<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505997</url>
  </required_header>
  <id_info>
    <org_study_id>ML-3341-118</org_study_id>
    <nct_id>NCT02505997</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects</brief_title>
  <official_title>A Phase I Study to Evaluate the Effect of Repeated Oral Doses of Delafloxacin on the Pharmacokinetics of a Single Oral Dose of Midazolam in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melinta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of repeated doses of oral delafloxacin on&#xD;
      the pharmacokinetic (PK) profile of a single oral dose of midazolam.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the effect of repeated doses of oral delafloxacin on the PK profile&#xD;
      of a single oral dose of midazolam. The study will also evaluate the pharmacokinetics,&#xD;
      safety, and tolerability of repeated oral doses of delafloxacin in healthy male and female&#xD;
      subjects and to obtain a steady state PK profile for oral delafloxacin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Midazolam and 1-hydroxymidazolam Plasma PK: AUC0-t</measure>
    <time_frame>Days 1 and 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Midazolam and 1-hydroxymidazolam Plasma PK: AUC0-inf</measure>
    <time_frame>Days 1 and 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Midazolam and 1-hydroxymidazolam Plasma PK: Cmax</measure>
    <time_frame>Days 1 and 8</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>VA Drug Interactions</condition>
  <arm_group>
    <arm_group_label>Midazolam/Delafloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.</description>
    <arm_group_label>Midazolam/Delafloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delafloxacin</intervention_name>
    <description>Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8</description>
    <arm_group_label>Midazolam/Delafloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No clinically important abnormal physical findings.&#xD;
&#xD;
          -  No clinically significant laboratory abnormalities.&#xD;
&#xD;
          -  Normal (or abnormal but not clinically significant) ECG measurements.&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2.&#xD;
&#xD;
          -  Normal (or abnormal but not clinically significant) blood pressure and pulse rate&#xD;
             measurements. methylxanthine-containing beverages or food&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any investigational drug within 8 weeks before administration of the first&#xD;
             dose of the study drug&#xD;
&#xD;
          -  Female who is pregnant, has a positive pregnancy test, or is breastfeeding.&#xD;
&#xD;
          -  Positive test result for amphetamines, barbiturates, benzodiazepines, cocaine&#xD;
             metabolites, opiates, cannabinoids, methylenedioxymethamphetamine, cotinine, or&#xD;
             alcohol in urine at Screening or Day -1.&#xD;
&#xD;
          -  Positive screening test for hepatitis B surface antigen, hepatitis C, and/or human&#xD;
             immunodeficiency virus antibodies.&#xD;
&#xD;
          -  Any surgical or medical condition that, in the judgment of the investigator, might&#xD;
             interfere with the absorption, distribution, metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Used any medication (prescription or over-the-counter, including health supplements&#xD;
             and herbal remedies, with the exception of acetaminophen, as defined in exclusion&#xD;
             number 8) within 2 weeks (4 weeks for drugs or substances known to inhibit or induce&#xD;
             CYP enzymes and/or P-gp including St. John's wort [Hypericum perforatum]) or 5&#xD;
             half-lives (whichever is longer) before the first dose of study drug.&#xD;
&#xD;
          -  Used an oral or IV antibiotic within 4 weeks of administration of the first dose of&#xD;
             the study drug.&#xD;
&#xD;
          -  Routinely or chronically used more than 2 g of acetaminophen daily.&#xD;
&#xD;
          -  Performed strenuous activity, sunbathing, and/or contact sports within 96 hours (4&#xD;
             days) before entry into the clinical study site on Day -1, and for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Donated or lost greater than 400 mL of blood in the 30 days before administration of&#xD;
             the first dose of the study drug.&#xD;
&#xD;
          -  History of clinically significant GI disease, or gastroenteritis (vomiting or&#xD;
             diarrhea) or any history of GI bleeding (excluding bleeding from hemorrhoids)&#xD;
&#xD;
          -  History of any significant drug allergy&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue Cammarata, MD</last_name>
    <role>Study Director</role>
    <affiliation>Melinta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

